RSI at 29 and the CFO Wrote His Biggest Check Yet

ISB Research · Favorable · sent to Ultimate members September 11, 2026

Relmada is a clinical-stage biotech testing a bladder cancer drug and a neurosteroid for other conditions, so this is binary-outcome territory where insider signals matter more than usual. The CFO just put $843,990 into the stock at $4.22, his third buy this year and the second insider stepping in over the past month. What makes it interesting is the setup underneath. RSI at 29, MFI at 23, price washed out to $4.07 against support at $4. History says the buyers here have a read. Insiders on this name have been right on 30-day moves close to 9 out of 10 times, averaging over 40% returns. Just know the 90-day picture flips negative, so this is a bounce trade off a beaten-down tape, not a set-and-forget hold. If you want defined risk, look at selling a put spread beneath his $4.22 to get paid while you wait.

Ultimate members received this analysis in real time.